{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:03:08Z","timestamp":1793124188354,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"15","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Risk estimation of different types of cardiovascular events (CVEs) following a hospitalization for exacerbated chronic obstructive pulmonary disease (exCOPD) is warranted to consider prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A case-crossover study was conducted using the French exhaustive hospital discharge database (2013\u201319). Case-patients had a diagnosis of chronic obstructive pulmonary disease, were hospitalized for a CVE in France in 2018\u201319 (admission date was index date) with no other CVE in \u226412 months, and had \u22651 hospitalization for exCOPD \u226424 weeks before index CVE. The key exposure was hospitalization for exCOPD (overall and according to levels of care intensity) \u22641\u20134 weeks vs. 9\u201324 weeks preceding the CVE. Conditional logistic regression models estimated odds ratios (ORs) for the association between hospitalization for exCOPD and different types of CVE. Among 9840 case-patients, the most frequent CVE was decompensated heart failure (5888 case-patients, 59.8%). The CVE risk was greater \u22644 weeks after a hospitalization for any exCOPD [OR, 3.03; 95% confidence interval (CI), 2.90\u20133.16] and seven times greater if mechanical ventilation was necessary (OR, 6.99; 95% CI, 6.09\u20138.03). The risk of non-ST-elevation myocardial infarction (OR, 5.33; 95% CI, 4.47\u20136.34) was the highest among CVE. The risk was also significantly increased (P &amp;lt;0.05) for many other CVEs: ST-elevation myocardial infarction (OR, 4.24), resuscitated cardiac arrest (OR, 4.33), pulmonary embolism (OR, 4.02), atrial fibrillation\/flutter (OR, 3.03), ischaemic stroke (OR, 1.93), and limb events (OR, 1.34). Ten percent of CVEs were fatal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Following hospitalization for exCOPD, the risk of cardiovascular complications is increased. These patients require close and sustained monitoring to mitigate CVE risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwaf086","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T15:23:04Z","timestamp":1739892184000},"page":"1436-1444","source":"Crossref","is-referenced-by-count":11,"title":["Risk of cardiovascular events according to the severity of an exacerbation of chronic obstructive pulmonary disease"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1459-2409","authenticated-orcid":false,"given":"Maeva","family":"Zysman","sequence":"first","affiliation":[{"name":"Service des maladies respiratoires, U1045, CIC 1401, Univ-Bordeaux, CHU de Bordeaux, H\u00f4pital Xavier Arnozan, Avenue du Haut L\u00e9v\u00e8que , 33600 Pessac ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clementine","family":"Nordon","sequence":"additional","affiliation":[{"name":"Global Evidence Strategy\u2014Respiratory, BioPharmaceuticals Medical, AstraZeneca , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Fabry-Vendrand","sequence":"additional","affiliation":[{"name":"Medical, AstraZeneca France , Courbevoie ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Rhodes","sequence":"additional","affiliation":[{"name":"Global Evidence Strategy\u2014Respiratory, BioPharmaceuticals Medical, AstraZeneca , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriane","family":"Bretin","sequence":"additional","affiliation":[{"name":"Real World Solution, IQVIA Op\u00e9rations , Courbevoie ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amayelle","family":"Rey","sequence":"additional","affiliation":[{"name":"Real World Solution, IQVIA Op\u00e9rations , Courbevoie ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Collin","sequence":"additional","affiliation":[{"name":"Real World Solution, IQVIA Op\u00e9rations , Courbevoie ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nolwenn","family":"Poccardi","sequence":"additional","affiliation":[{"name":"Medical, AstraZeneca France , Courbevoie ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0322-9818","authenticated-orcid":false,"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dupuytren University Hospital, and EpiMaCT, Inserm1094\/IRD270, Limoges University , Limoges ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"2025102719572366700_zwaf086-B1","author":"Global Initiative for Chronic Obstructive Lung Disease"},{"key":"2025102719572366700_zwaf086-B2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2147\/COPD.S236787","article-title":"Identification of patient profiles with high risk of hospital re-admissions for acute COPD exacerbations (AECOPD) in France using a machine learning model","volume":"15","author":"Cavailles","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025102719572366700_zwaf086-B3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/17476348.2021.1840982","article-title":"Advances in understanding of mechanisms related to increased cardiovascular risk in COPD","volume":"15","author":"Rogliani","year":"2021","journal-title":"Expert Rev Respir Med"},{"key":"2025102719572366700_zwaf086-B4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1164\/rccm.201201-0034OC","article-title":"Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease","volume":"186","author":"Divo","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2025102719572366700_zwaf086-B5","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S2213-2600(23)00261-8","article-title":"COPD and multimorbidity: recognising and addressing a syndemic occurrence","volume":"11","author":"Fabbri","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2025102719572366700_zwaf086-B6","doi-asserted-by":"crossref","first-page":"1801261","DOI":"10.1183\/13993003.01261-2018","article-title":"What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement","volume":"52","author":"Kim","year":"2018","journal-title":"Eur Respir J"},{"key":"2025102719572366700_zwaf086-B7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12931-018-0944-3","article-title":"Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial","volume":"19","author":"Watz","year":"2018","journal-title":"Respir Res"},{"key":"2025102719572366700_zwaf086-B8","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/thorax-2022-219039","article-title":"Frequency and severity of respiratory infections prior to COPD diagnosis and risk of subsequent postdiagnosis COPD exacerbations and mortality: EXACOS-UK health care data study","volume":"78","author":"Whittaker","year":"2023","journal-title":"Thorax"},{"key":"2025102719572366700_zwaf086-B9","first-page":"621","article-title":"Hospitalizations for COPD exacerbations: trends and determinants of death","volume":"12","author":"Molinari","year":"2015","journal-title":"COPD"},{"key":"2025102719572366700_zwaf086-B10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/COPD.S438893","article-title":"Risk of death and cardiovascular events following an exacerbation of COPD: the EXACOS-CV US study","volume":"19","author":"Daniels","year":"2024","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025102719572366700_zwaf086-B11","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1164\/rccm.202307-1122OC","article-title":"Temporal risk of nonfatal cardiovascular events after chronic obstructive pulmonary disease exacerbation: a population-based study","volume":"209","author":"Graul","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2025102719572366700_zwaf086-B12","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/heartjnl-2023-323487","article-title":"Heightened long-term cardiovascular risks after exacerbation of chronic obstructive pulmonary disease","volume":"110","author":"Hawkins","year":"2024","journal-title":"Heart"},{"key":"2025102719572366700_zwaf086-B13","doi-asserted-by":"crossref","first-page":"e002153","DOI":"10.1136\/bmjresp-2023-002153","article-title":"Elucidating the risk of cardiopulmonary consequences of an exacerbation of COPD: results of the EXACOS-CV study in Germany","volume":"11","author":"Vogelmeier","year":"2024","journal-title":"BMJ Open Respir Res"},{"key":"2025102719572366700_zwaf086-B14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/oxfordjournals.aje.a115853","article-title":"The case-crossover design: a method for studying transient effects on the risk of acute events","volume":"133","author":"Maclure","year":"1991","journal-title":"Am J Epidemiol"},{"key":"2025102719572366700_zwaf086-B15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"2025102719572366700_zwaf086-B16","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/ije\/dyw359","article-title":"Data resource profile: the French national uniform hospital discharge data set database (PMSI)","volume":"46","author":"Boudemaghe","year":"2017","journal-title":"Int J Epidemiol"},{"key":"2025102719572366700_zwaf086-B17","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025102719572366700_zwaf086-B18","volume-title":"Etude des algorithmes de definition de pathologies dans le Syst\u00e8me National d\u2019Information Interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM)","author":"Quantin","year":"2015"},{"key":"2025102719572366700_zwaf086-B19","first-page":"1","article-title":"D\u00e9lib\u00e9ration n\u00b0 2018-257 du 7 juin 2018 portant homologation d'une m\u00e9thodologie de r\u00e9f\u00e9rence relative aux traitements de donn\u00e9es n\u00e9cessitant l'acc\u00e8s pour le compte des personnes produisant ou commercialisant des produits mentionn\u00e9s au II de l'article L. 5311-1 du code de la sant\u00e9 publique aux donn\u00e9es du PMSI centralis\u00e9es et mises \u00e0 disposition par l'ATIH par l'interm\u00e9diaire d'une solution s\u00e9curis\u00e9e (MR 006)","volume":"112","author":"CNIL d","year":"2018","journal-title":"JORF"},{"key":"2025102719572366700_zwaf086-B20","author":"Fuhrman"},{"key":"2025102719572366700_zwaf086-B21","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/resp.13620","article-title":"Increased risk of major adverse cardiac events following the onset of acute exacerbations of COPD","volume":"24","author":"Reilev","year":"2019","journal-title":"Respirology"},{"key":"2025102719572366700_zwaf086-B22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2458-9-33","article-title":"Ecological association between a deprivation index and mortality in France over the period 1997\u20132001: variations with spatial scale, degree of urbanicity, age, gender and cause of death","volume":"9","author":"Rey","year":"2009","journal-title":"BMC Public Health"},{"key":"2025102719572366700_zwaf086-B23","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/joim.12186","article-title":"Use of self-controlled designs in pharmacoepidemiology","volume":"275","author":"Hallas","year":"2014","journal-title":"J Intern Med"},{"key":"2025102719572366700_zwaf086-B24","doi-asserted-by":"crossref","first-page":"106094","DOI":"10.1016\/j.rmed.2020.106094","article-title":"Acute exacerbations of COPD are associated with a prothrombotic state through platelet-monocyte complexes, endothelial activation and increased thrombin generation","volume":"171","author":"van der Vorm","year":"2020","journal-title":"Respir Med"},{"key":"2025102719572366700_zwaf086-B25","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1165\/rcmb.2010-0169OC","article-title":"Acute lung injury induces cardiovascular dysfunction: effects of IL-6 and budesonide\/formoterol","volume":"45","author":"Suda","year":"2011","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2025102719572366700_zwaf086-B26","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1001\/jamacardio.2018.0095","article-title":"Associations of obstructive sleep apnea with atrial fibrillation and continuous positive airway pressure treatment: a review","volume":"3","author":"Linz","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2025102719572366700_zwaf086-B27","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.3390\/jcm11113180","article-title":"Hypercapnia in COPD: causes, consequences, and therapy","volume":"11","author":"Csoma","year":"2022","journal-title":"J Clin Med"},{"key":"2025102719572366700_zwaf086-B28","doi-asserted-by":"crossref","first-page":"A5","DOI":"10.1093\/eurheartjsupp\/suac117","article-title":"Influenza and cardiovascular disease pathophysiology: strings attached","volume":"25","author":"Skaarup","year":"2023","journal-title":"Eur Heart J Suppl"},{"key":"2025102719572366700_zwaf086-B29","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jamainternmed.2024.0212","article-title":"Acute cardiac events in hospitalized older adults with respiratory syncytial virus infection","volume":"184","author":"Woodruff","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2025102719572366700_zwaf086-B30","doi-asserted-by":"crossref","first-page":"180063","DOI":"10.1183\/16000617.0063-2018","article-title":"Respiratory viral infection: a potential \u201cmissing link\u201d in the pathogenesis of COPD","volume":"28","author":"Linden","year":"2019","journal-title":"Eur Respir Rev"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf086\/62013737\/zwaf086.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/32\/15\/1436\/62013737\/zwaf086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/32\/15\/1436\/62013737\/zwaf086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:57:33Z","timestamp":1761609453000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/32\/15\/1436\/8026617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":30,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,2,20]]},"published-print":{"date-parts":[[2025,10,28]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwaf086","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,2,20]]}}}